drugset / Trial / NCT03548337

Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

NCT03548337

Phase 4 Completed 301 enrolled Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

A Phase 4 Study To Describe The Safety, Tolerability, And Immunogenicity Of 13- Valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials When Given With Routine Pediatric Vaccines In Healthy Infants In India

Timeline

Start
2018-05-31
Primary completion
2019-12-20
Completion
2019-12-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prevnar 13 Vaccine

Indications

No indication recorded.